Recombinant Guinea pig Voltage-dependent L-type calcium channel subunit alpha-1C (CACNA1C), partial

What is CACNA1C and what is its fundamental function in cellular physiology?

CACNA1C is the gene encoding the pore-forming alpha-1C subunit of voltage-gated calcium channels that specifically gives rise to L-type calcium currents. The protein functions as a critical mediator of calcium ion influx into the cytoplasm, which subsequently triggers calcium release from intracellular stores such as the sarcoplasmic reticulum. This calcium signaling cascade is essential for numerous physiological processes, particularly in excitable cells. In cardiac tissue, CACNA1C plays a pivotal role in excitation-contraction coupling, while in vascular smooth muscle, it contributes significantly to the regulation of vascular tone and blood pressure. The channel belongs to the "high-voltage activated" (HVA) group of calcium channels, requiring substantial membrane depolarization for activation .

What are the structural characteristics of recombinant Guinea pig CACNA1C protein?

The recombinant Guinea pig CACNA1C protein available for research is typically produced as a fragment protein spanning amino acids 1-169. This protein fragment is expressed in cell-free systems with ≥85% purity and is suitable for SDS-PAGE analysis. The amino acid sequence of this fragment is: F Q E Q G E Q E Y K N C E L D K N Q R Q C V E Y A L K A R P L R R Y I P I S I T F F R L F R V M R L V K L L S R G E G I R T L L W T F I K S F Q A L P Y V A L L I V M L F F I Y A V I G M Q V F G K I A L N D T T E I N R N N N F Q T F P Q A V L L L F R C A T G E A W Q D I M L A C M P G K K R A P E S E P S N S T E G E T P C G S S F A V F Y . This sequence represents a portion of the channel that contributes to voltage sensing and channel gating properties, making it valuable for structural studies, antibody production, and protein-protein interaction experiments.

How does CACNA1C contribute to cardiac function and pathophysiology?

CACNA1C plays multiple essential roles in cardiac physiology, functioning as a primary mediator of calcium entry during the plateau phase of the cardiac action potential. Through research with both native and recombinant channels, we understand that CACNA1C is required for normal heart development and the regulation of heart rhythm. The channel initiates excitation-contraction coupling by mediating calcium influx, which then triggers calcium-induced calcium release from the sarcoplasmic reticulum via ryanodine receptors . Dysregulation or mutations in CACNA1C can lead to cardiac pathologies, including Brugada syndrome, where specific variants are associated with shorter QTc intervals compared to SCN5A carriers . Methodologically, researchers investigating cardiac CACNA1C function commonly employ isolated ventricular myocytes from guinea pigs using whole-cell voltage-clamp techniques to characterize channel properties under various conditions, including response to pharmacological agents such as dihydropyridines .

What electrophysiological methods best characterize CACNA1C functional properties?

For rigorous characterization of CACNA1C functional properties, whole-cell voltage-clamp recordings represent the gold standard methodology. As demonstrated in studies using guinea pig ventricular myocytes, this approach allows for examination of voltage-dependent and use-dependent modulation of channel activity. When implementing this method, researchers should consider several technical parameters: (1) Selection of charge carrier (1.8 mM Ba²⁺ or Ca²⁺) affects current magnitudes and kinetics; (2) Holding potential critically influences channel availability and drug responses - studies show striking differences in channel behavior between -60 mV and -30 mV holding potentials; (3) Stimulation frequency impacts use-dependent effects - studies at 2 Hz have revealed important use-dependent behaviors . For pharmacological studies, concentration-response relationships should be established (e.g., EC₅₀ values of 177 nM for peak current enhancement and 10.2 nM for shifts in voltage-dependent inactivation have been determined for the dihydropyridine (+)-202-791) . Protocols should systematically assess activation, inactivation, and recovery from inactivation to fully characterize channel gating kinetics.

How do mutations in CACNA1C affect channel function and disease phenotypes?

Mutations in CACNA1C can significantly alter channel function, leading to diverse pathophysiological consequences. Functional characterization of CACNA1C variants has revealed that many disease-associated mutations result in reduced peak calcium currents compared to wild-type channels. Specific mutations such as p.T320M, p.Q428E, p.E850D, p.E850del, p.N1255S, p.A1648T, p.A1717G, p.R1880Q, p.R1973Q, and p.G2084E have been functionally characterized through whole-cell current recording techniques . These functional alterations correlate with clinical phenotypes, particularly in Brugada syndrome. Notably, in the subgroup of Brugada syndrome patients with QTc intervals in the lowest quartile, the prevalence of CACNA1C variants was significantly higher (12.9%) . Methodologically, researchers investigating mutation effects should employ heterologous expression systems for wild-type and mutant channels, paired with electrophysiological characterization and trafficking studies. Additionally, patient-derived iPSCs differentiated into cardiomyocytes provide a more physiologically relevant context for evaluating mutation consequences in the appropriate cellular background.

What are the molecular mechanisms underlying CACNA1C splice variant diversity and their functional implications?

CACNA1C exhibits remarkable molecular diversity through alternative splicing, with different cell types expressing distinct channel variants optimized for their specific physiological roles. Recent research using novel approaches to examine full-length CACNA1C molecules has revealed that the single CACNA1C gene encodes a substantially larger "family" of related calcium channel proteins than previously recognized, particularly in human brain tissue . This diversity arises from the cell-specific "reading" of the genome, resulting in the shuffling of basic instructions to generate precise molecular variants tailored to cellular needs. Methodologically, researchers investigating CACNA1C splice variants should employ RNA sequencing approaches that can capture full-length transcripts rather than fragmentary analysis. This approach overcomes previous technical limitations that only allowed examination of small pieces of the shuffled molecules, necessitating speculation about how these fragments were combined . For functional characterization of splice variants, electrophysiological assessment should be paired with cell-type specific expression profiling to establish correlations between splice variant expression patterns and functional properties in native tissues.

What genetic manipulation approaches are effective for studying CACNA1C in animal models?

For targeted genetic manipulation of CACNA1C in animal models, viral vector-mediated Cre-loxP recombination systems have proven highly effective. A well-established protocol involves manual bilateral infusion of AAV2/2-Cre-GFP into the hippocampus of cacna1c floxed/floxed mice using precisely defined stereotaxic coordinates (anterior–posterior −2 mm; media–lateral ±1.6 mm; dorsal–ventral −1.8 mm, at a 10° angle) . This approach allows for spatially and temporally controlled knockout of CACNA1C. Several methodological considerations are crucial for successful implementation: (1) A slow infusion rate (0.1 μl/min) with a 5-minute post-infusion dwell time ensures complete virus delivery; (2) A minimum 3-week expression period is necessary to achieve maximal Cre recombinase activity; (3) AAV2/2-GFP serves as an appropriate control vector . For subsequent tissue analysis, GFP visualization enables precise dissection of affected regions, and qPCR with CACNA1C-specific primers (e.g., Qiagen QuantiTect Primer assay QT00150752) can confirm knockdown efficiency. This genetic approach provides a powerful tool for investigating CACNA1C's role in specific brain regions and neuropsychiatric phenotypes.

How can researchers effectively characterize pharmacological modulation of CACNA1C?

For robust characterization of pharmacological modulation of CACNA1C, researchers should implement comprehensive voltage-clamp protocols that capture both voltage-dependent and use-dependent effects. Studies with dihydropyridines such as (+)-202-791 have revealed complex modulatory patterns that depend critically on experimental conditions. A systematic approach should include: (1) Concentration-response curves from multiple holding potentials to identify potential biphasic effects; (2) Steady-state inactivation protocols to quantify shifts in voltage-dependent availability; (3) Activation protocols to assess changes in voltage-dependent gating; (4) Repetitive depolarization protocols at various frequencies to evaluate use-dependent effects . Data analysis should determine EC₅₀ values for multiple parameters, as studies have shown that compounds can have different potencies for distinct effects (e.g., EC₅₀ of 177 nM for peak current enhancement versus 10.2 nM for shifts in inactivation curves) . Additionally, researchers should consider testing both enantiomers of chiral compounds and evaluating potential cooperative interactions between stereoisomers, which may reveal important pharmacological properties that inform therapeutic development.

What approaches are most effective for studying CACNA1C isoform diversity in human tissues?

Studying CACNA1C isoform diversity in human tissues requires specialized approaches that overcome traditional technical limitations. Until recently, researchers could only examine small fragments of spliced molecules, necessitating inference about how these fragments were assembled in full-length channels . A more effective methodology employs techniques designed specifically to capture and analyze full-length CACNA1C transcripts. This approach has revealed unexpected complexity in the channel variants encoded by the CACNA1C gene, particularly in human brain tissue. For tissue acquisition, researchers should develop protocols for rapid post-mortem tissue processing to minimize RNA degradation. RNA extraction methods optimized for long transcripts, such as those used in the Tunbridge lab's research, are essential for capturing the full diversity of CACNA1C isoforms . Following extraction, long-read sequencing technologies provide advantages over short-read methods for resolving complex splicing patterns. For functional characterization, cloning and expression of full-length isoforms in heterologous systems, coupled with electrophysiological assessment, enables correlation of structural differences with functional properties.

What are common challenges when working with recombinant CACNA1C and how can they be addressed?

Working with recombinant CACNA1C presents several technical challenges that researchers should anticipate and address methodically. Protein stability issues are common, as channel proteins can be susceptible to degradation. To minimize this, researchers should: (1) Store the recombinant protein (≥85% purity) at appropriate temperatures following manufacturer recommendations; (2) Minimize freeze-thaw cycles; (3) Use protease inhibitors when appropriate . For experimental applications, establishing appropriate positive controls is essential for validating antibody specificity and functional assays. When performing SDS-PAGE analysis, the recombinant fragment's expected molecular weight should be verified against standards . For heterologous expression systems, researchers often encounter trafficking issues where mutant channels show reduced surface expression. This can be addressed through: (1) Addition of trafficking-promoting chaperones; (2) Temperature manipulation during expression; (3) Pharmacological rescue with channel ligands. For electrophysiological studies, low current densities may necessitate signal optimization through altered ionic conditions (e.g., higher Ba²⁺ concentrations as charge carrier) or expression system adjustments.

How can researchers differentiate between CACNA1C-derived pathologies and phenocopies in clinical studies?

Differentiating CACNA1C-derived pathologies from phenocopies requires a multifaceted approach combining genetic, functional, and clinical analyses. For Brugada syndrome research, evidence indicates that patients with CACNA1C variants exhibit characteristic electrocardiographic features distinct from other genetic subtypes. Specifically, CACNA1C variant carriers tend to have QTc intervals in the lower range of normal distribution compared to SCN5A carriers . This electrophysiological signature can help identify potential CACNA1C-related cases. Methodologically, researchers should implement: (1) Comprehensive genetic screening covering all known disease-associated genes; (2) Detailed phenotypic characterization, including specific ECG parameters; (3) Functional studies of identified variants using whole-cell electrophysiology to confirm causality . Statistical approaches should include subgroup analyses based on genetic findings, as demonstrated in studies where patients were stratified by QTc quartiles, revealing that 12.9% of patients in the lowest QTc quartile harbored CACNA1C variants . For neuropsychiatric conditions, where CACNA1C is a widely reproduced risk gene , researchers should employ similar strategies combining detailed phenotyping with genetic and functional assessments to distinguish CACNA1C-specific effects from other etiologies.

What emerging technologies offer new insights into CACNA1C structure-function relationships?

Several cutting-edge technologies are expanding our ability to investigate CACNA1C structure-function relationships at unprecedented resolution. Cryo-electron microscopy now enables visualization of calcium channel complexes at near-atomic resolution, providing insights into how structural domains contribute to gating, permeation, and drug binding. For CACNA1C research, this technology could reveal how disease-associated mutations structurally perturb channel function and how different splice variants adopt distinct conformations. Methodologically, researchers pursuing structural studies should consider: (1) Expression systems optimized for protein yield and stability; (2) Purification strategies that preserve native protein interactions; (3) Computational approaches for modeling structural dynamics based on static structures . Additionally, the development of optical methods for monitoring calcium channel activity in intact cells, including genetically encoded calcium indicators and voltage sensors, provides new opportunities for studying CACNA1C function in more physiologically relevant contexts. CRISPR-based approaches for introducing specific mutations or tagged versions of CACNA1C into native genomic contexts also represent powerful tools for investigating structure-function relationships in appropriate cellular backgrounds.

How can insights from CACNA1C research translate into therapeutic approaches for associated disorders?

Translating CACNA1C research into therapeutic approaches requires systematic investigation of channel modulators with disease-specific targets. For Brugada syndrome, where CACNA1C variants are associated with reduced channel function and characteristic ECG patterns , potential therapeutic strategies should focus on compounds that enhance channel activity or correct trafficking defects of mutant channels. Research methodology should include: (1) High-throughput screening for compounds that rescue defective channel function; (2) Structure-based drug design targeting specific channel domains; (3) Validation in patient-derived cellular models. For neuropsychiatric disorders associated with CACNA1C variants , a more nuanced approach is needed given the complex role of calcium signaling in neural function. Researchers should employ region-specific and cell-type-specific CACNA1C manipulation in animal models, as demonstrated with AAV-mediated approaches targeting the hippocampus . This enables evaluation of circuit-specific effects that might be targeted therapeutically. Additionally, induced pluripotent stem cell (iPSC) models from patients with CACNA1C variants provide platforms for testing compound efficacy in disease-relevant cellular contexts, offering a translational bridge between basic channel research and clinical applications.